Advertisement

 

 

Salivary evaluation in radioactive I(131) treated patients with thyroid carcinoma.

Salivary evaluation in radioactive I(131) treated patients with thyroid carcinoma.
Author Information (click to view)

Daniel FI, Lima LD, Grando LJ, Castro R, Cordeiro EAK, Dos Santos CR,


Daniel FI, Lima LD, Grando LJ, Castro R, Cordeiro EAK, Dos Santos CR, (click to view)

Daniel FI, Lima LD, Grando LJ, Castro R, Cordeiro EAK, Dos Santos CR,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Acta odontologica Scandinavica 2017 11 10() 1-5 doi 10.1080/00016357.2017.1399214

Abstract
BACKGROUND AND OBJECTIVE
radioiodine treatment (I(131)) used to treat thyroid carcinomas produces side effects (sialadenitis, xerostomia, dysphagia and caries susceptibility) reflecting in a poor patient quality of life. This study aimed to evaluate the effect of I(131) on salivary function and possible oral impairment.

MATERIAL AND METHODS
Thirty-seven patients undergoing I(131) were submitted to oral examination, answer questions regarding xerostomia/hyposalivation and collect saliva at three moments (M1: 30-45 days before I(131), M2: 1-2 days after I(131) and M3: 7-10 days after treatment). Saliva was assayed for flow rate and calcium/phosphate concentrations.

RESULTS AND CONCLUSIONS
significant difference in calcium/phosphate concentration was shown between M1 and M2, with evident decrease at M2. Flow rate reduced right after treatment with 41% of patients returning to previous rate at M3 (no statistical difference). A higher number of patients related xerostomia and difficulty in swallowing food at M2. The results showed that xerostomia/hyposalivation, dysphagia and calcium/phosphate concentration decrease may be considered early radioiodine side effects.

Submit a Comment

Your email address will not be published. Required fields are marked *

five × 2 =

[ HIDE/SHOW ]